Lumenis Be., a leading energy-based medical device company for aesthetic and eye care solutions, announced a new partnership with Bosley, the largest hair restoration practice in the United States and a recognized leader in the industry. Bosley becomes the first national hair restoration medical practice in the United States to offer FoLix™, the first and only FDA-cleared fractional laser for hair loss treatment.
Bosley will initially offer FoLix at its Beverly Hills location beginning September 2024 and plans to roll out the service at its other locations across the country over time. This partnership initiates a new era in hair loss treatment by introducing the first FDA-cleared fractional laser solution for hair loss to U.S. customers for the first time, potentially benefiting more than 80 million people affected by hair loss across the country1. The partnership also highlights Bosley’s dedication to supporting customers in their fight against hair loss, reinforcing its position as one of the world’s most trusted and experienced hair restoration experts.
“Staying at the forefront of innovations and excellence, we are always looking for the latest and most effective advancements to support our customers in their hair restoration journey,” said Rob Spurrell, CEO and President of Bosley. “FoLix is a strong and perfect fit for our expanding range of solutions, as it offers a non-surgical, in-office approach with minimal discomfort, showing promising results in several monthly sessions.”
“At Bosley, we understand the profound impact that hair loss can have on our patients’ lives. We have been helping patients with hair loss, surgically and non-surgically, with emerging technology for 50 years, and we are excited to introduce the Lumenis FoLix treatment, an innovative treatment designed to help our patients restore their hair and confidence,” said Ken Washenik, MD PhD, Chief Medical Officer at Bosley.
Following the FDA clearance granted earlier this year, Lumenis launched FoLix, a groundbreaking innovation in hair loss treatment and the first of its kind. Developed with Lumenis’ proprietary technology, FoLix offers a non-invasive, effective, simple, and safe solution that uses a unique approach to deliver precise pulses of laser light that leverage the body’s natural processes to stimulate hair follicles. FoLix is anticipated to attract considerable interest from people impacted by hair loss, as it offers results through 4-6 monthly sessions with no chemicals, needles, anesthesia, or downtime.
Lumenis and Bosley are both committed to raising awareness and educating about the causes, prevention, and treatment of hair loss. Hair loss is a common condition that could appear in various stages of life, with 2 in 3 men facing hair loss by age 352 and 1 in 2 women facing hair loss by age 503. The introduction of FoLix meets this strong clinical need and can have a significant impact on people’s self-esteem, confidence, and quality of life.
“With proven results from Lumenis’ pre-clinical and clinical studies, FoLix represents a significant leap forward in the world of hair restoration for both patients and providers,” said Brad Oliver, President of Lumenis Americas. “Our partnership with Bosley is an exciting first step in bringing FoLix to the U.S. market, and we are confident that this revolutionary technology will make a meaningful difference in the lives of millions of people who suffer from hair loss, empowering them to take control and grow more confident in their everyday experiences.”
